Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis

BACKGROUND: Tacrolimus is a second-line immunosuppressant in myasthenia gravis (MG) therapy, which is mainly used in combination with corticosteroids to reduce steroid dose and maintain the effect of immunotherapy. However, few studies have focused on the effect of tacrolimus as single-agent immunot...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Weiwei, Peng, Yuyao, Jin, Wanlin, Ouyang, Song, Yang, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627335/
https://www.ncbi.nlm.nih.gov/pubmed/34845439
http://dx.doi.org/10.1155/2021/9138548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627335/
https://www.ncbi.nlm.nih.gov/pubmed/34845439
http://dx.doi.org/10.1155/2021/9138548

Ejemplares similares